Newsletter RSS

Mealey's Drugs & Devices

  • March 12, 2026

    Depo-Provera MDL Judge Updates Status Of Pilot Cases, Number Of Cases Filed

    PENSACOLA, Fla. — More than 3,700 plaintiffs across state courts and in a multidistrict litigation centralized in a Florida federal court allege that Depo-Provera, a long-lasting injectable contraceptive, caused women to develop intracranial meningiomas, a type of brain tumor, according to a recent case management order.

  • March 12, 2026

    Mass. Case Alleging Suturing Device’s Needle Broke During Surgery Moves Forward

    BOSTON — A woman who alleges that a suturing device’s needle broke off during her surgery made claims that “are not preempted by federal law, and that are supported by sufficient factual allegations to make out viable tort causes of action,” a Massachusetts state court justice held in denying a motion to dismiss filed by the manufacturers.

  • March 12, 2026

    Parties Agree To Terms For Selecting Defective Port MDL Bellwether Cases

    SAN DIEGO — Parties involved in a multidistrict litigation of cases that allege that chemotherapy ports were defective and caused a multitude of injuries agreed to which type of cases will be selected for bellwether cases, according to a joint statement filed in a California federal court.

  • March 12, 2026

    Louisiana, Woman Urge Rejection Of Mifepristone Makers’ Motions To Dismiss

    LAFAYETTE, La. — Louisiana and Rosalie Markezich, a woman who claims she was forced to take mifepristone that was mailed to Louisiana, “have alleged concrete sovereign and economic injuries traceable” to the U.S. Food and Drug Administration’s 2023 decision to remove the in-person dispensing requirement for mifepristone, they argue in opposition to motions to dismiss filed by the drug’s manufacturers.

  • March 10, 2026

    Novo Nordisk Drops Suit Against Hims, Enters Agreement For Online Sales

    WILMINGTON, Del. — The manufacturer of Ozempic, Wegovy and Rybelsus on March 9 told a Delaware federal court that it agreed to dismiss all claims against Hims & Hers Health Inc. and Hims Inc. (collectively, Hims) stemming from its marketing and sale of compounded semaglutide for weight loss the same day the parties announced a partnership that will allow the sale of those drugs on the online health care provider’s website.

  • March 10, 2026

    CPAP MDL Judge Won’t Reopen Case For Man Who Says He Didn’t Get Court’s Notices

    PITTSBURGH — A man and his attorney were unable to convince the federal judge overseeing the multidistrict litigation involving the recall of approximately 10.8 million continuous positive air pressure (CPAP) sleep apnea devices to reopen his case after it was dismissed for failing to respond to orders to show cause.

  • March 09, 2026

    Judge Grants FDA Summary Judgment In Row Over Drug Exclusion From Bulk List

    FORT WORTH, Texas — An outsourcing facility that neither compounds sodium thiosulfate “nor has a facility capable of doing so” lacks standing to challenge a decision by the U.S. Food and Drug Administration to decline to add the drug to a list of bulk drug substances approved for compounding, a Texas federal judge ruled in granting summary judgment to the government (FarmaKeio Outsourcing, LLC v. United States Food And Drug Administration, et al., No. 2401040, N.D. Texas, 2026 U.S. Dist. LEXIS 46434).

  • March 09, 2026

    States Seek To Vacate New CDC Vaccine Recommendations, Advisory Committee Overhaul

    PHOENIX — Contending that the changes to the Centers for Disease Control and Prevention’s vaccine recommendations were made without the use of the usual science-based protocols and that recent appointments to the Advisory Committee on Immunization Practices (ACIP) made by U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. were in violation of the Federal Advisory Committee Act (FACA), several states and the governor of Pennsylvania sued the HHS, CDC, Kennedy and other federal officials seeking to set aside the recommendation changes and committee appointments as arbitrary, capricious and contrary to law in violation of the Administrative Procedure Act (APA).

  • March 06, 2026

    Merck Waives Right To Respond To High Court Petition Over Untimely Gardasil Claims

    WASHINGTON, D.C. — The manufacturer of the Gardasil vaccine on March 5 declined to respond to a petition for a writ of certiorari in the U.S. Supreme Court filed by three women who claim that the Fourth Circuit U.S. Court of Appeals erred in finding that the women must first file in the Vaccine Act compensation program before suing in a district court and contend that the addition of the Gardasil vaccine to the Vaccine Injury Table was unconstitutional.

  • March 05, 2026

    Mass Tort Cases For Drugs, Medical Devices

    New developments in the following mass tort drug and device cases are marked in boldface type.

  • March 05, 2026

    Teva Renews Interlocutory Appeal Motion On Preemption In Paragard IUD MDL

    ATLANTA — Teva Pharmaceuticals USA Inc. renewed its motion to certify an order for interlocutory appeal to the 11th Circuit U.S. Court of Appeals of a ruling in the Paragard intrauterine device (IUD) multidistrict litigation that information can retroactively apply as newly acquired information under the U.S. Food and Drug Administration’s changes-being-effected (CBE) regulation.

  • March 05, 2026

    FDA Files Supplemental Brief In Row Over Its Rules For Mifepristone Dispensing

    LAFAYETTE, La. — The federal government outlined the procedure for how the U.S. Food and Drug Administration can issue interim orders if it obtains information about drugs that have been previously approved in response to a request for supplemental briefs by the Louisiana federal judge overseeing a case brought by the state and one of its residents that challenges the validity of the FDA’s 2023 decision to remove the in-person dispensing requirement for mifepristone.

  • March 05, 2026

    Parties Say Other Side In Public Nuisance Opioid Case Gets 4th Circuit Opinion Wrong

    HUNTINGTON, W.Va. — Three national drug distributors and two West Virginia counties that sued them for causing a public nuisance through their over-distribution of opioids filed separate briefs with a West Virginia federal court, both arguing that the other side misunderstands a decision by the Fourth Circuit U.S. Court of Appeals that remanded the case to the district court.

  • March 04, 2026

    Sanofi Gets Interlocutory Appeal For Preemption Question In Taxotere Eye Injury MDL

    NEW ORLEANS — The Louisiana federal judge overseeing the multidistrict litigation involving cases alleging that a chemotherapy drug caused eye injuries granted an unopposed motion filed by the manufacturer to certify an order for interlocutory appeal of the denial of its motion for summary judgment on preemption grounds.

  • March 04, 2026

    1st Circuit Affirms Dismissal Of Boston’s Opioid Suit Against PBMs As Time-Barred

    BOSTON — The First Circuit U.S. Court of Appeals affirmed a lower court’s ruling that dismissed Boston’s claims against pharmacy benefit managers (PBMs) for contributing to the opioid epidemic as time-barred and further ruled that the lower court did not err in refusing to disqualify Motley Rice LLC from representing Boston and others in the suit.

  • March 03, 2026

    Judge Dismisses Complaint Alleging Abbott Shared Medical Data With Google, Meta

    CHICAGO — An Illinois federal judge on March 2 dismissed with prejudice a complaint filed by three individuals who alleged that the manufacturer of continuous glucose monitoring devices for diabetes management shared sensitive information about them to third parties through tracking tools on its website.

  • March 03, 2026

    Judge Gives Final Approval To $7.75M Settlement In Stock-Drop Class Action

    NEW YORK — A federal judge in New York granted final approval to a $7.75 million settlement in a class action brought by investors against a biopharmaceutical company and certain of its current and former executives that alleged that the defendants made false and misleading statements that caused the company’s stock price to drop and investors to lose money.

  • February 27, 2026

    Both Parties To CDC Vaccine Changes Dispute Resist Vaccine Critic Intervention

    BOSTON — Both the government and physicians’ professional groups and others challenging the Centers for Disease Control and Prevention’s changes to vaccine recommendations on Feb. 26 opposed the emergency motion to intervene as defendants and counterclaim plaintiffs filed by a children’s advocacy group known for questioning the safety and efficacy of vaccinations and others who claimed that their interests were not properly protected by the current parties.

  • February 27, 2026

    Judge Says Texas Suit Against Tylenol Maker On ASD/ADHD Link Can Move Forward

    CARTHAGE, Texas — A Texas state court judge on Feb. 26 rejected a motion filed by the maker of Tylenol to dismiss a complaint filed by Texas alleging that the company hid information about the dangers of acetaminophen and its link to autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD) and violated the state’s consumer protection law by deceptively marketing the drug as the only safe product for pain relief for pregnant women.

  • February 27, 2026

    Judge Finds Claims Against Medical Device Maker Preempted, Not Correctly Pleaded

    LAS CRUCES, N.M. — A man’s amended complaint alleging that he was injured by a defective spinal cord stimulator (SCS) has been dismissed without prejudice by a federal judge in New Mexico who found that his claims are either preempted by federal law or inadequately pleaded.

  • February 27, 2026

    Judge Rules Materials Science Expert Can Testify For Bard In Port Catheter MDL

    PHOENIX — The Arizona federal judge overseeing the multidistrict litigation involving C.R. Bard Inc.’s implanted port catheter (IPC) device denied a motion filed by the plaintiffs to exclude an expert in materials science after finding that the expert properly used a reliable methodology in reaching his conclusions.

  • February 27, 2026

    Del. Supreme Court Won’t Step In To Slow Down Consolidated Depo-Provera Cases

    DOVER, Del. — The Delaware Supreme Court on Feb. 25 refused to hear an interlocutory appeal filed by two law firms representing certain plaintiffs in a consolidated state court case alleging that a long-lasting injectable contraceptive caused women to develop intracranial meningiomas, a type of brain tumor, leaving stand a case management order intended to help streamline the hundreds of cases expected to be filed in the state.

  • February 26, 2026

    Judge Signs Off On Diet Drug Settlement Between Novo Nordisk, Arkansas Clinic

    FAYETTEVILLE, Ark. — A federal judge in Arkansas on Feb. 25 signed off on a final judgment to settle false advertising and unfair and deceptive trade practices claims filed by the manufacturer of Ozempic, Wegovy and Rybelsus against a company that sells compounded drugs for weight loss that it advertises as the same as or equivalent to the manufacturer’s prescription diet and diabetes drugs.

  • February 25, 2026

    Novo Nordisk, Arkansas Clinic Settle Case Involving Compounded Semaglutide

    FAYETTEVILLE, Ark. — The manufacturer of Ozempic, Wegovy and Rybelsus and a company that sells compounded drugs for weight loss that it advertises as the same as or equivalent to the manufacturer’s prescription diet and diabetes drugs have reached a confidential settlement agreement to end claims for false advertising and unfair and deceptive trade practices, according to a joint motion filed in an Arkansas federal court.

  • February 25, 2026

    Hims & Hers Faces Putative Class Action Over Misleading Diet Drug Advertisements

    CHICAGO — An online provider of compounded semaglutide for weight loss misled “consumers into believing its product is just as safe and effective as Ozempic® and Wegovy®, including because it uses ‘the same active ingredient,’ which is false,” two Illinois residents allege in a putative class action filed in an Illinois federal court.